EMA Authorised: Samsca (tolvaptan) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

Tolvaptan (Samsca) has been authorised by the EMA for the treatment of Inappropriate Antidiuretic Hormone Syndrome (SIADH).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inappropriate Antidiuretic Hormone Syndrome

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Status: Authorised. Therapeutic area: Inappropriate ADH Syndrome. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 18/08/2026